Practical radiation oncology 2017
Radiotherapeutic management of vestibular schwannomas using size- and location-adapted fractionation regimens to maximize the therapeutic ratio.
Abstract
Background
We evaluated and compared the radiographic and clinical outcomes of patients with vestibular schwannomas treated with single fraction stereotactic radiosurgery (SRS), 5 fractions of hypofractionated stereotactic radiation therapy (hSRT), or 25 to 30 fractions of conventionally fractionated stereotactic radiation therapy (cfSRT).
Methods and materials
Fifty-six patients treated with LINAC-based SRS (median, 12.5 Gy), hSRT (25 Gy), or cfSRT (median, 54 Gy) were retrospectively reviewed. Fractionation was based on the size of the tumor, proximity to the brainstem, and potential risk of neurological sequelae. Median follow-up time was 55.2 months.
Results
The pretreatment median tumor diameter was significantly smaller for SRS (1.14 cm) compared with hSRT (1.7 cm) (P = .03) and cfSRT (2.0 cm) (P < .001). The overall local tumor control was 96.4%: 100% SRS, 100% hSRT, and 90% cfSRT (P = .19). Tumor regression was observed in 53.3% of SRS, 76.2% of hSRT, and 90% of cfSRT (P = .05). There was less transient expansion of tumors treated with cfSRT (5%) than with SRS (53.3%) or hSRT (28.6%) (P = .005). The median time to regression was 13.8 months for SRS, 14.2 months for hSRT, and 5.5 months for cfSRT (P = .34). There was a 3.6% incidence of grade 3 trigeminal neuropathy, but there was no grade 3 facial neuropathy.
Conclusions
All 3 regimens demonstrated similar excellent local control with minimal toxicity; however, the ability of hSRT to treat larger tumors with comparable outcomes to SRS and greater patient convenience when compared with cfSRT suggest that hSRT may offer the optimal treatment approach.
Related Questions
What is the role of radiation in intra labyrinthine (cochlear) schwannoma?
This is a bit of a tricky question to answer without knowing the size of the lesion, the age of the patient, their current symptoms, and whether they have serviceable hearing.If the tumor is small, and the patient has residual serviceable hearing, it might be best to delay treatment and order a repe...
Would you prefer SBRT or fractionated radiation for a sacral peripheral nerve sheath tumor?
For a sacral peripheral nerve sheath tumor, I would favor SBRT (Stereotactic Body Radiation Therapy) over fractionated radiation due to its ability to deliver a high dose of radiation precisely to the tumor while minimizing damage to surrounding healthy tissues, especially in a sensitive area like t...
How do you manage an intramedullary benign nerve sheath tumor post sub-total resection seen on post-operative MRI?
Intracranial schwannomas respond well to low dose SRS (11.5-12 Gy) or SRT (25 Gy in 5 fractions) Slane et al., PMID 28089525 However, both of these approaches use a somewhat higher dose than the spinal cord tolerance doses. Therefore, I would treat the patient on a radiation delivery system equippe...